Mylan lands injunction against GSK’s Paroxetine
The US District Court for the District of New Jersey has granted Mylan its motion for a permanent injunction against GlaxoSmithKline’s (GSK’s) Paroxetine CR.
Paroxetine CR is a generic version of GSK’s antidepressant Paxil CR (paroxetine hydrochloride).
The court ordered that GSK may not supply the product to generic drug company Apotex, which had been marketing Paroxetine CR in the US as an authorised generic.
It also allowed Mylan to determine the amount of additional damages it had suffered since September 30, 2013 as a result of GSK’s breach.
Mylan had been awarded $106 million in damages in a settlement related to the case in March 2014.
According to a statement by Mylan, it is the only company to have successfully developed a generic version of Paxil that has been approved by the US Food and Drug Administration.
